Navigation Links
Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
Date:5/20/2008

tructures. All Synta drug candidates were invented by Synta scientists using our compound library and drug discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead investigational drug candidate, elesclomol, which is in a global, pivotal Phase III clinical trial for the treatment of metastatic melanoma. For more information, please visit http://www.syntapharma.com.

GlaxoSmithKline Cautionary Statement Regarding Forward-Looking Statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2007.

Synta Pharmaceuticals Corp. Safe Harbor Statement

This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements can be identified by the use of forward-looking terminology such as "will", "would", "should", "expects", "anticipates", "intends", "plans", "believes", "may", "estimates", "predicts", "projects", or similar expressions intended to identify forward-looking statements. Such statements, including statements relating to the timing and progress of our clinical and preclinical programs, reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in "Risk Factors" of our Form 10-K for the year ended December 31, 2007 as filed
'/>"/>

SOURCE GlaxoSmithKline; Synta Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
2. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
3. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
4. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
5. Amikacin Inhale Shows Promising Results in Phase II Study
6. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
7. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
8. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
9. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
10. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
11. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... LAUSANNE , Suisse, October 1, 2014 /PRNewswire/ ... génomique clinique et dans le domaine de l,analyse ... a lancé aujourd,hui une solution de diagnostic in ... d,exécuter une analyse complète de la mucoviscidose dans ... d,identifier et de caractériser tous les types de ...
(Date:9/30/2014)... report analyzes the worldwide markets for Enteral Feeding Devices in ... Nasogastric Tubes, and Others. The report provides separate ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for the period ... for these markets. The report profiles 38 companies ...
(Date:9/30/2014)... , Sept. 30, 2014 MiMedx Group, Inc. ... company utilizing human amniotic tissue and patent-protected processes to ... Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and ... Koob , Ph.D., Chief Scientific Officer, will present at ... will present on Tuesday, October 7, 2014, at 5:00PM ...
Breaking Medicine Technology:Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19MiMedx to Present at the Stem Cell Meeting on the Mesa 2
... in Glasgow,have devised a new method of attacking ... of Clinical Investigation* today,(Thursday). , A team of ... mice a chemical that caused cancer cells to ... they were,carrying. The chemical kick started a gene ...
... Development Plans - , ,OTTAWA, Canada – March ... specializing in developing,advanced products related to High Density ... of,the Phase I/II Clinical Trial of its lead ... of dyslipidemia and heart,disease. , ,Results showed, to ...
Cached Medicine Technology:Scottish Scientists Test ‘Secret Weapon’ Against,Tumours 2Scottish Scientists Test ‘Secret Weapon’ Against,Tumours 3Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 2Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 3
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post explaining how ... Senior citizens can purchase a joint life insurance policy ... joint policy is cheaper, but will only pay benefits ... insurance can be used to cover important funeral expenses. ... as the application process is simple and straightforward. ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post ... for smokers. , Smoking will always have a negative ... the best method to find affordable coverage. Insurance brokerage ... coverage. , Whole life insurance premiums will be ... the coverage is permanent, the initial rates are ...
(Date:10/1/2014)... ATLANTA (PRWEB) October 01, 2014 ... executive networking and relationship-marketing firm, announced today ... Security Executive® and Project of the Year ... decision makers representing organizations in financial services, ... include large-scale technology endeavors that address key ...
(Date:10/1/2014)... DURHAM, N.C. A new genetic finding from Duke ... hostility, anxiety and depression might also be hard-wired to ... diabetes and heart disease. , An estimated 13 percent ... the genetic susceptibility, and knowing this could help them ... healthy diet, exercise and stress management. , "Genetic susceptibility, ...
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
Breaking Medicine News(10 mins):Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... survey which has sought to understand sexual behaviors has ... sex //in the present day are baseless and monogamy ... this survey are published in The Lancet. ... showed that many had just a single recent sexual ...
... grown from umbilical cord blood stem cells for the first ... experiments for drug testing. ,According to the scientists, ... just the initial phase of generating segments that can be ... mature functioning form. ,Scientists from Newcastle University ...
... always been the tourism industry with the scenic beauty of ... ,The latest buzzword in Kerala is medical tourism ... combination of fun and well. ,Tourists like 50-year-old ... Kerala’s medical tourism. ,When Anderson came to Kerala ...
... reluctant to seek medical treatment to correct the malady, a ... men found erectile problems affected 50 percent of men over ... China Morning Post said. ,But Andrew Yip Wai-chun, ... Wah Group of Hospitals, who released details of the study, ...
... has identified a key enzyme responsible for triggering a ... to new study findings published online// this week in ... Virginia Commonwealth University, the Hospital for Special Surgery and ... stage for development of new strategies and target therapies ...
... from breast cancer but who may not have the main ... higher than average risk of developing the disease. ... the BRCA1 and BRCA2 faults, they may be three times ... age of 50 than other women. ,Professor ...
Cached Medicine News:Health News:Artificial Liver from Cord Blood Stem cells 2Health News:Kerala to Venture into Medical Tourism 2Health News:Key Signaling Switch Identified in Allergic Disease 2Health News:Breast Cancer linked to Gene Risk 2
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Solid 13.5 mm wide by 5 mm deep blades. Edge of blades serrated. Dull finish....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 11 mm blades. Dull finish. Most popular size or model....
Medicine Products: